Bruker agrees to acquire ELITechGroup for €870M enterprise value; Q2 2024 close expected

BRUKER CORP

Enterprise Value of €870 million; cash purchase price with cash on hand.
Target projected 2023 revenue of €150M, majority recurring; accretive to non-GAAP EPS in FY2024.
Put option exercisable after French and Dutch works council consultations; 12-month exclusivity.
Bruker provided equity commitment letter and secured W&I insurance for seller reps.
Acquisition is subject to regulatory approvals and carve-out of clinical chemistry business.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.